DLJ14, a novel chemo-sensitization agent, enhances therapeutic effects of adriamycin against MCF-7/A cells both in vitro and in vivo

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 3, 2014, Pages 398-407

  Zhang, Peng ^a   Zheng, Bei Bei ^a   Wang, Hong Yuan ^a   Chen, Jin Hua ^a   Liu, Xin Yong ^a   Guo, Xiu Li ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

(E) 2 (2,4 dimethoxystyryl) 3,5,6 trimethylpyrazine (DLJ14); Adr resistant human breast cancer cell (MCF 7 A cell); glutathione S transferase (GST ); multiple drug resistance; tumour xenograft

Indexed keywords

(E)-2-(2,4-DIMETHOXYSTYRYL)-3,5,6-TRIMETHYLPYRAZINE (DLJ14); ADR-RESISTANT HUMAN BREAST CANCER CELL (MCF-7/A CELL); GLUTATHIONE S-TRANSFERASE Π (GSTΠ); MULTIPLE DRUG RESISTANCE; TUMOUR XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HERB-DRUG INTERACTIONS; HUMANS; LIGUSTICUM; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHYTOTHERAPY; PLANT EXTRACTS; PYRAZINES;

EID: 84894258268     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12168     Document Type: Article

References (36)

1. Neidle S, Thurston DE,. Chemical approaches to the discovery and development of cancer therapies. Nat Rev Cancer 2005; 5: 285-296.
2. Rajamanickam S, Agarwal R,. Natural products and colon cancer: current status and future prospects. Drug Dev Res 2008; 69: 460-471.
3. O'Connor R,. The pharmacology of cancer resistance. Anticancer Res 2007; 27: 1267-1272.
4. Borowski E, et al. Strategies for overcoming ABC-transporter-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim Pol 2005; 52: 609-627.
5. Lyons RM, et al. Oral ezatiostat HCI (Telintra®, TLK199) and idiopathic chronic neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor. J Hematol Oncol 2011; 4: 43-47.
6. Zhang FY, et al. Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein. Pharm Res 2009; 26: 914-925.
7. Szakács G, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-234.
8. Yu ST, et al. Downregulation of GSTpi expression by tryptanthrin contributing to sensitization of doxorubicin-resistant MCF-7 cells through c-jun NH2-terminal kinase-mediated apoptosis. Anticancer Drugs 2009; 20: 382-388.
9. Xi GM, et al. Bisbibenzyl derivatives sensitize vincristine-resistant KB/VCR cells to chemotherapeutic agents by retarding P-gp activity. Bioorg Med Chem 2010; 18: 6725-6733.
10. Luqmani YA,. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005; 14: 35-48.
11. Ballerini S, et al. Analysis of GSTP1-1 polymorphism using real-time polymerase chain reaction. Clin Chim Acta 2003; 329: 127-132.
12. Mavis CK, et al. Expression level and DNA methylation status of glutathione S-transferase genes in normal murine prostate and TRAMP tumors. Prostate 2009; 69: 1312-1324.
13. Kalinina EV, et al. Expression of genes for redox-dependent glutathione S-transferase isoforms GSTP1-1 and GSTA4-4 in tumor cell during the development doxorubicin resistance. Bull Exp Biol Med 2007; 143: 328-330.
14. Yu ST, et al. Downregulation of GST pi expression by tryptanthrin contributing to sensitization of doxorubicin-resistant MCF-7 cells through c-jun NH(2)-terminal kinase-mediated apoptosis. Anti Cancer Drugs 2009; 20: 382-388.
15. Song YN, et al. Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GST π activity. Toxicol in Vitro 2011; 25: 937-943.
16. Townsend DM, et al. Novel role for glutathione S-transferase pi. Regulator of protein S-Glutathionylation following oxidative and nitrosative stress. J Biol Chem 2009; 284: 436-445.
17. Adler V, et al. Regulation of JNK signaling by GSTp. EMBO J 1999; 18: 1321-1334.
18. Nqoei KR, et al. Characterization of a novel JNK (c-Jun N-terminal kinase) inhibitory peptide. Biochem J 2011; 434: 399-413.
19. Deng L, et al. Ligustrazine derivatives. Part 4: design, synthesis, and biological evaluation of novel ligustrazine-based stilbene derivatives as potential cardiovascular agents. Chem Biol Drug Des 2012; 79: 731-739.
20. Kamal A, et al. 3-substituted 2-phenylimidazo [2,1-b] benzothiazoles: synthesis, anticancer activity, and inhibition of tubulin polymerization. Chem Med Chem 2012; 7: 292-300.
21. Xiong X, et al. Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo. Invest New Drugs 2009; 27: 1-11.
22. Kato Y, et al. Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. Cancer Biol Ther 2007; 6: 891-897.
23. Burg D, et al. Peptide-bond modified glutathione conjugate analogs modulate GSTp function in GSH-conjugation, drug sensitivity and JNK signaling. Biochem Pharmacol 2006; 71: 268-277.
24. Ji BS, et al. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Life Sci 2005; 77: 2221-2232.
25. Orriss IR, et al. Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem 2009; 106: 109-118.
26. Malki A, El Ashry el S,. Quinuclidinone derivative 6 induced apoptosis in human breast cancer cells via sphingomyelinase and JNK signaling. J Chemother 2012; 24: 268-278.
27. Nishinaka T, et al. Curcumin activates human glutathione S-transferase P1 expression through antioxidant response element. Toxicol Lett 2007; 170: 238-247.
28. Shi LX, et al. Reversal effect of tyroservatide (YSV) tripeptide on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU. Cancer Lett 2008; 269: 101-110.
29. Dedes KJ, et al. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer 2011; 47: 138-150.
30. Bhaskar A, et al. Expression of measles virus nucleoprotein induces apoptosis and modulates diverse functional protein in cultured mammalian cells. PLoS ONE 2011; 6: e18765.
31. Jemal A, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
32. Wind NS, Holen I,. Multidrug resistance in breast cancer: from in vitro models to clinical studies. Int J Breast Cancer 2011; 2011: 967419.
33. Hastak K, et al. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly (ADP-ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 2010; 70: 7970-7980.
34. Zhao D, et al. Arsenic trioxide reduces drug rsistance to adriamycin in leukemic K562/A02 cells via multiple mechanisms. Biomed Pharmacother 2011; 65: 354-358.
35. Cui H, et al. 4-Aryl-1,3,2-oxathiazolylium-5-olate: a novel GST inhibitor to release JNK and activate c-JNK for cancer therapy. Cancer Chemother Pharmacol 2008; 62: 509-515.
36. Tuna G, et al. Inhibition characteristics of hypericin on rat small intestine glutathione-S-transferases. Chem Biol Interact 2010; 188: 59-65.